On March 16, 2009, the Food and Drug Administration granted tentative approval to a generic formulation of lamivudine tablets, 150 mg, for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. The drug is manufactured by Alkem Labs Ltd., of Mumbai, India.
The details can be read here.
No comments:
Post a Comment